Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular
endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent
inhibitory effects on multiple human tumor xenografts. This first-in-human study is conducted
to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the
pharmacokinetics , safety and preliminary anti-tumor activity of HMPL-013 at single doses and
multiple doses .